Komori
Olympus (7733) · RiskMitigated

Litigation and Damages Risks Relating to Chinese Production Subsidiaries

First written in FY2019-Q1. 3 of 8 entries say "Worsened", first in FY2019-Q2. Latest entry: FY2025-H1.

8entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2019-Q1 – FY2020MitigatedFY2021-Q1OtherFY2022WorsenedFY20232018: 220182019: 120192020: 220202021: 020212022: 120222023: 120232024: 12024
Same theme, other companies
Litigation and Litigation-Related Loss RiskA theme 300 companies write about · 302 as a headwind · 0 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 302 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1MitigatedAnnual report

    「A court settlement was reached between our consolidated subsidiary Olympus (Shenzhen) Industrial Ltd. and Shenzhen Anpingtai Investment Development Co., Ltd. to conclude the appeal proceedings, and we reversed the provision previously recognized to provide for losses relating to the litigation.」

    A court settlement was reached to conclude the appeal proceedings relating to the Chinese manufacturing subsidiary, and a provision of ¥1.308 billion was reversed.
  2. FY2023WorsenedAnnual report

    「Our consolidated subsidiary Olympus (Shenzhen) Industrial Ltd. is involved in 2 business disputes in total with Shenzhen Anpingtai Investment Development Co., Ltd. and Shenzhen YL Technology Co., Ltd. Depending on the future course of the proceedings, these matters may affect the business performance and financial condition of our Group.」

    Regarding litigation and dispute risks relating to the Chinese manufacturing subsidiary, we stated that 2 business disputes in total were pending.
  3. FY2022Remand judgment; appeal ongoingAnnual report

    「A judgment was issued on 31 December 2021. We appealed the first-instance judgment after remand on 24 January 2022, as we were dissatisfied with it, and the appeal is currently pending. However, depending on the future course of the proceedings, the matter may affect the business performance and financial condition of our Group.」

    The litigation relating to the Chinese manufacturing subsidiary remains on appeal after the remand judgment, and the proceedings are still pending.
  4. FY2021-Q1MitigatedAnnual report

    「On 1 July 2020, the Guangdong Provincial Higher People's Court issued a ruling setting aside the first-instance judgment and remanding the case for retrial, on the grounds that, among others, the facts on which Anpingtai based its claim were unclear. However, depending on the future course of the proceedings, the matter may affect the business performance and financial condition of our Group.」

    The first-instance judgment in the litigation relating to the Chinese manufacturing subsidiary was set aside and the case was remanded for retrial. The litigation risk continues, but the procedural status has changed from the previous damages judgment.
  5. FY2020MaterialisedAnnual report

    「Olympus (Shenzhen) Industrial Ltd., our consolidated sub-subsidiary in China, has been served with a complaint in litigation brought by Shenzhen YL Technology Co., Ltd.」

    Following the termination of the OSZ equity transfer agreement, YL brought new litigation and served the complaint. The Company stated that there would be no impact on its business performance.
  6. FY2019-Q3WorsenedAnnual report

    「Although the judgment upheld some of the claims made by our consolidated subsidiary, it ordered the payment of damages. Accordingly, we reasonably estimated the amount deemed necessary to provide for losses relating to the litigation and recorded ¥3,828 million as other expenses.」

    The provision for litigation losses relating to the Chinese manufacturing subsidiary increased from ¥3.793 billion to ¥3.828 billion.
  7. FY2019-Q2WorsenedAnnual report

    「In the litigation between our consolidated subsidiary Olympus (Shenzhen) Industrial Ltd. and Shenzhen Anpingtai Investment Development Co., Ltd., a judgment was issued by the Shenzhen Intermediate People's Court on 30 July 2018 and served on 3 August of the same year. Although the judgment upheld some of the claims made by our consolidated subsidiary, it ordered the payment of damages. Accordingly, we reasonably estimated the amount deemed necessary to provide for losses relating to the litigation and recorded ¥3,793 million as other expenses.」

    Following the damages judgment relating to the Chinese manufacturing subsidiary, the litigation provision increased from ¥3.457 billion to ¥3.793 billion.
  8. FY2019-Q1MaterialisedAnnual report

    「In the litigation between our consolidated subsidiary Olympus (Shenzhen) Industrial Ltd. and Shenzhen Anpingtai Investment Development Co., Ltd., a judgment was issued by the Shenzhen Intermediate People's Court on 30 July 2018 and served on 3 August of the same year. Although the judgment upheld some of the claims made by our consolidated subsidiary, it ordered the payment of damages. Accordingly, we reasonably estimated the amount deemed necessary to provide for losses relating to the litigation and recorded ¥3,457 million as other expenses.」

    A damages judgment was issued in litigation relating to a Chinese manufacturing subsidiary, and ¥3.457 billion was recorded as a loss, marking the occurrence and crystallization of a new risk.
Moved together

"CSR Priority Areas Focused on Healthcare and Health" moved the same way as this thread, in the same document, in 3 of its 8 moves.

333222★123456
  1. ★This thread
  2. 1CSR Priority Areas Focused on Healthcare and Health3×
  3. 2Structural Reform of the Imaging Business and Stable Profitability3×
  4. 3Risk to the Video Business from Production Bases in China and Vietnam3×
  5. 4Risk of Failing to Respond to Changes in Healthcare Systems and Regulations in Each Country2×
  6. 5Maintaining Competitiveness in Gastrointestinal Endoscopy and Growing the Treatment Device and Surgical Businesses2×
  7. 6Risks from Emerging-Market Slowdown, Yen Appreciation and Falling Resource Prices2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Olympus yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.